Advanced search
Publication Cover
Breast Cancer: Targets and Therapy Volume 6, 2014 - Issue
Submit an article Journal homepage
119
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer

David D Stenehjem1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA;2 Huntsman Cancer Institute, Salt Lake City, UT, USACorrespondence[email protected]
,
Minkyoung Yoo1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA
,
Sudhir K Unni1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA
,
Mukul Singhal1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA
,
Hillevi Bauer1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA
,
Kim Saverno1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA
,
Cheng Quah3 Genentech, Inc., South San Francisco, CA, USA
,
Anthony Masaquel3 Genentech, Inc., South San Francisco, CA, USA
&
Diana I Brixner1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA;4 Program in Personalized Health Care, University of Utah, Salt Lake City, UT, USA
 show all
Pages 169-177 | Published online: 29 Oct 2014

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Anton E. Andersson, Barbro Linderholm & Daniel Giglio. (2021) Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab. Acta Oncologica 60:4, pages 475-481.
Read now

Articles from other publishers (6)

Yiqun Han, Yun Wu, Hangcheng Xu, Jiayu Wang & Binghe Xu. (2022) The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. International Journal of Clinical Oncology 27:4, pages 707-716.
Crossref
Tatiane Cristofolini, Milene Dalmina, Jelver A. Sierra, Adny H. Silva, André A. Pasa, Frederico Pittella & Tânia B. Creczynski-Pasa. (2020) Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells. Materials Science and Engineering: C 109, pages 110555.
Crossref
Tomasz Jodlowski & K. H. Ramesh. 2019. Molecular Diagnostics in Cancer Patients. Molecular Diagnostics in Cancer Patients 237 268 .
Antony P. Martin, Jennifer Downing, Madeleine Cochrane, Brendan Collins, Ben Francis, Alan Haycox, Ana Alfirevic & Munir Pirmohamed. (2018) Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies. Critical Reviews in Oncology/Hematology 130, pages 92-107.
Crossref
Gaetano Romano. (2015) Tumor markers currently utilized in cancer care. Materials and Methods 5.
Crossref
Min Yan, Maria Schwaederle, David Arguello, Sherri Z. Millis, Zoran Gatalica & Razelle Kurzrock. (2015) HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer and Metastasis Reviews 34:1, pages 157-164.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.